ISRG Intuitive Surgical Earnings: Q2 2026 Results

Intuitive Surgical, Inc. reported its Q2 2026 earnings on April 20, 2026. The medical device leader, known for its da Vinci Surgical System, continues to dominate minimally invasive surgery. ISRG stock trades at $465.60, down 0.77% on the day. With a market cap of $165.37 billion, the company remains a healthcare heavyweight. Meyka AI rates ISRG with a grade of B+. Investors are watching closely as the surgical robotics market expands globally.

ISRG Q2 2026 Earnings Results Overview

Intuitive Surgical reported mixed signals in its latest earnings announcement. The company faced challenges meeting analyst expectations this quarter. Specific EPS and revenue figures were not yet disclosed at the time of this report.

Recent Quarter Performance

The most recent completed quarter showed strong execution. In Q1 2026, ISRG beat EPS estimates by $0.26, posting $2.53 versus the $2.27 estimate. Revenue also exceeded expectations at $2.866 billion against a $2.763 billion estimate. This represents a $103 million revenue beat, or 3.7% above guidance. The company demonstrated pricing power and strong demand for its surgical systems.

Comparison to Prior Quarters

Looking back, ISRG has consistently beaten estimates. In Q4 2025, the company posted $2.19 EPS versus $1.93 expected, a $0.26 beat. Revenue came in at $2.44 billion against $2.351 billion guidance. Q3 2025 showed $1.81 EPS beating $1.74 estimates. This track record suggests strong operational momentum and execution.

Financial Metrics and Valuation Signals

Intuitive Surgical trades at elevated multiples reflecting its market leadership. The stock commands a premium valuation typical of high-growth medical device companies. Understanding these metrics helps investors assess fair value.

Valuation Multiples

ISRG trades at a P/E ratio of 59.09, significantly above the S&P 500 average. The price-to-sales ratio stands at 16.38, indicating investors pay $16.38 for every dollar of revenue. The PEG ratio of 13.99 suggests the stock is expensive relative to growth rates. However, the company’s strong profitability justifies some premium. Net profit margin reaches 28.4%, among the best in medical devices.

Profitability and Cash Generation

The company generates robust cash flows. Operating cash flow per share totals $8.54, while free cash flow per share reaches $7.02. Return on equity stands at 16.4%, showing efficient capital deployment. The company maintains a fortress balance sheet with minimal debt. Current ratio of 4.87 indicates strong liquidity for investments and shareholder returns.

Growth Trajectory and Market Dynamics

Intuitive Surgical demonstrates consistent growth across multiple dimensions. The surgical robotics market continues expanding as hospitals adopt minimally invasive procedures. ISRG benefits from favorable demographic and procedural trends.

Revenue and Earnings Growth

Full-year 2025 revenue grew 20.5% year-over-year, accelerating from prior periods. Net income expanded 23.0%, outpacing revenue growth through operational leverage. EPS grew 22.3%, benefiting from modest share buybacks. Free cash flow surged 91%, reflecting improved working capital management. These growth rates exceed typical medical device industry averages of 5-8%.

Long-Term Growth Outlook

Over five years, ISRG revenue per share grew 127%, or 18.2% annually. Net income per share expanded 165%, or 21.3% annually. This demonstrates the company’s ability to grow faster than the market. The da Vinci system installed base continues expanding globally. Procedure volumes remain strong as surgeons gain experience with robotic platforms.

Stock Performance and Analyst Sentiment

ISRG stock has experienced volatility recently, though long-term trends remain positive. Analyst consensus remains constructive despite near-term headwinds. The market continues to value the company’s competitive moat.

Recent Price Action

ISRG trades at $465.60, down 0.77% today but up 1.6% over six months. Year-to-date performance shows a 17.8% decline from January levels. The 52-week range spans $427.84 to $603.88, showing significant volatility. Trading volume of 2.44 million shares exceeds the 30-day average of 1.91 million, indicating active interest. The stock remains well above its 200-day moving average of $503.09.

Analyst Consensus and Ratings

Wall Street remains bullish on ISRG. Fifteen analysts rate the stock as Buy, while four recommend Hold. Only two analysts maintain Sell ratings. The consensus rating translates to 3.0 on a 5-point scale, indicating Buy. Meyka AI rates ISRG with a B+ grade, suggesting the stock offers value at current levels. The company’s strong competitive position supports the constructive outlook.

Final Thoughts

Intuitive Surgical maintains its position as the surgical robotics leader despite recent stock volatility. The company’s consistent earnings beats, robust cash generation, and 20%+ revenue growth demonstrate operational excellence. ISRG trades at premium valuations reflecting its market dominance and growth prospects. With 15 Buy ratings from analysts and a Meyka AI B+ grade, the stock appeals to growth-oriented investors. The minimally invasive surgery market remains in early innings, offering long-term tailwinds. Near-term stock weakness may present buying opportunities for patient investors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.